Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act regarding changes in number of votes

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 26 July, 2011 at 5.00 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act regarding changes in number of votes

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a
notification regarding changes in number of votes in accordance with Chapter 2,
Section 9 of the Finnish Securities Markets Act, described below.

The notification received by the Company concerns the changes in voting rights
of Abingworth Management Limited (through Abingworth Bioventures IV LP and
Abingworth Bioventures IV Executives LP) in the Company. The holdings of shares
in the Company by Abingworth Management Limited (through Abingworth Bioventures
IV LP and Abingworth Bioventures IV Executives LP) continue to be below 1/20, as
previously.

As a result of the changes in the number of voting rights announced on 18 March
2011, 6 June 2011 and 7 July 2011 the number of votes in the Company by
Abingworth Management Limited (through Abingworth Bioventures IV LP and
Abingworth Bioventures IV Executives LP) has decreased below 1/20.

Name          Number of    Number of    Number of   (%) of  Number of   (%) of
              shares       voting       shares      shares  voting      voting
              before       rights       after       after   rights      rights
                           before                           after       after

Abingworth
Management
Limited       16.693.258   16.693.258   16.693.258  4.66    16.693.258  4.66
(through
Abingworth
Bioventures
IV LP and
Abingworth
Bioventures
IV Executives
LP) in total



The number of voting rights and percentages presented above are calculated
without taking into account the treasury shares held by the Company or its group
companies.

On the date hereof, the registered number of shares in Biotie is 387,594,457. Of
these shares 11,880,224 are held by the Company or its group companies.

Turku, 26 July 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1533503]